KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) FCF Margin (2018 - 2025)

Vir Biotechnology's FCF Margin history spans 8 years, with the latest figure at 40.93% for Q4 2025.

  • For Q4 2025, FCF Margin rose 68341.0% year-over-year to 40.93%; the TTM value through Dec 2025 reached 578.52%, up 7394.0%, while the annual FY2025 figure was 578.52%, 3283.0% up from the prior year.
  • FCF Margin for Q4 2025 was 40.93% at Vir Biotechnology, up from 69952.92% in the prior quarter.
  • Across five years, FCF Margin topped out at 2312.48% in Q2 2022 and bottomed at 69952.92% in Q3 2025.
  • The 5-year median for FCF Margin is 433.64% (2023), against an average of 5655.19%.
  • The largest annual shift saw FCF Margin surged 794723bps in 2024 before it tumbled -6263157bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 1.21% in 2021, then surged by 3876bps to 45.64% in 2022, then crashed by -1529bps to 652.06% in 2023, then fell by -11bps to 724.34% in 2024, then surged by 94bps to 40.93% in 2025.
  • Per Business Quant, the three most recent readings for VIR's FCF Margin are 40.93% (Q4 2025), 69952.92% (Q3 2025), and 10111.78% (Q2 2025).